Press Releases

Apr 27, 2023
BASKING RIDGE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J.
Apr 19, 2023
BASKING RIDGE, NJ (April 19, 2023)  – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announces its participation in the upcoming
Apr 18, 2023
The iLSTA Trial is the first study combining LSTA1 with standard-of-care chemotherapy and immunotherapy WARPNINE to provide funding and local trial management BASKING RIDGE, N.J. and SUBIACO, Australia, April 18, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc.
Mar 27, 2023
Check out this recent episode of Columbia Surgery’s podcast Conversations and Curbsides where Dr. Kazuki Sugahara joins Dr. Hyesoo Lowe to discuss the difficulty of treating pancreatic cancer tumors, and how drug delivery systems can potentially improve both chemotherapy and immunotherapy.
Displaying 1 - 10 of 12